News
TRYPF
0.047
-0.64%
-0.000
Tryp Therapeutics Set To Finalize Merger With Exopharm, Announces Trading Halt Ahead Of ASX Listing
Tryp Therapeutics Inc. Is a Canadian biotech leader in psychedelics. The company has received approval from shareholders for their strategic merger with Exopharm Limited. The completion of the merger is set for May 1, 2024. Tryp will voluntarily halt trading of its shares on the Canadian Securities Exchange.
Benzinga · 1d ago
Tryp Therapeutics Moves Forward with Exopharm Merger
TipRanks · 2d ago
Weekly Report: what happened at TRYPF last week (0415-0419)?
Weekly Report · 4d ago
Weekly Report: what happened at TRYPF last week (0408-0412)?
Weekly Report · 04/15 11:55
Weekly Report: what happened at TRYPF last week (0401-0405)?
Weekly Report · 04/08 12:01
Weekly Report: what happened at TRYPF last week (0325-0329)?
Weekly Report · 04/01 11:58
Weekly Report: what happened at TRYPF last week (0318-0322)?
Weekly Report · 03/25 12:02
Weekly Report: what happened at TRYPF last week (0311-0315)?
Weekly Report · 03/18 12:00
Tryp Therapeutics Shareholders Approve Major Deal
TipRanks · 03/13 05:07
Weekly Report: what happened at TRYPF last week (0304-0308)?
Weekly Report · 03/11 11:55
Weekly Report: what happened at TRYPF last week (0226-0301)?
Weekly Report · 03/04 11:59
Weekly Report: what happened at TRYPF last week (0219-0223)?
Weekly Report · 02/26 12:17
Weekly Report: what happened at TRYPF last week (0212-0216)?
Weekly Report · 02/19 12:19
Weekly Report: what happened at TRYPF last week (0205-0209)?
Weekly Report · 02/12 12:05
Weekly Report: what happened at TRYPF last week (0129-0202)?
Weekly Report · 02/05 12:17
Weekly Report: what happened at TRYPF last week (0122-0126)?
Weekly Report · 01/29 12:01
Weekly Report: what happened at TRYPF last week (0115-0119)?
Weekly Report · 01/22 12:06
Weekly Report: what happened at TRYPF last week (0108-0112)?
Weekly Report · 01/15 12:01
Tryp Therapeutics Explores Psilocybin's Potential In New Trials To Treat IBS And Fibromyalgia
Psychedelics biotech Tryp Therapeutics is advancing its psilocybin-based portfolio in Australia. The company has received approval for a Phase 1 study on its IV-infused psilocin for the psychedelic state. Tryp will soon begin its Phase 2a clinical trial on oral psilokbin for abdominal pain related to IBS and fibromyalgia.
Benzinga · 01/08 21:22
Weekly Report: what happened at TRYPF last week (0101-0105)?
Weekly Report · 01/08 12:07
More
Webull provides a variety of real-time TRYPF stock news. You can receive the latest news about Tryp Therapeutic through multiple platforms. This information may help you make smarter investment decisions.
About TRYPF
Tryp Therapeutics Inc. is a Canada-based clinical stage pharmaceutical company. The Company is focused on developing compounds for the treatment of rare or orphan diseases and other diseases with unmet medical needs. Its lead development program, psilocybinfor-neuropsychiatry (PFN) program, is designed to treat neuropsychiatric disorders through the dosing of formulations of synthetic psilocybin. The indication for its PFN program is fibromyalgia. The Company is also evaluating additional indications for its PFN program, including hyperphagia in Prader Willi syndrome (PWS) and other neuropsychiatric-based chronic pain conditions and eating disorders. The Company is also engaged in developing a formulation of razoxane for the treatment of soft tissue sarcomas.